Emerade products may fail to deliver adrenaline doses due to needle blockage, the Medicines and Healthcare Products Regulatory Agency (MHRA) has warned.
The government agency on Thursday issued a class 4 pharmacy level caution in use for Emerade 150, 300 and 500 micrograms solution for injection in pre-filled syringe, by Bausch & Lomb UK.
The issue, considered as a rare event, was first detected in June, last year during a routine stability testing. However, MHRA says the pens are not being recalled as there are not enough replacements available.
Community pharmacy teams are advised to inform patients to carry two in-date adrenaline auto-injectors with them at all times.
An MHRA statement said: “Healthcare professionals should contact all patients, and their carers, who have been supplied with an Emerade device to inform them of the potential defect and reinforce the advice to always carry two in-date adrenaline auto-injectors with them at all times.”